PT  - JOURNAL ARTICLE
AU  - S Steffenrud
TI  - Metabolism of 9-deoxo-16,16-dimethyl-9-methylene prostaglandin E2 in humans.
DP  - 1983 May 01
TA  - Drug Metabolism and Disposition
PG  - 255--265
VI  - 11
IP  - 3
4099  - http://dmd.aspetjournals.org/content/11/3/255.short
4100  - http://dmd.aspetjournals.org/content/11/3/255.full
SO  - Drug Metab Dispos1983 May 01; 11
AB  - Tritium-labeled 9-deoxo-16,16-dimethyl-9-methylene prostaglandin E2 was administered by intravenous injection into humans. The initial half-life in plasma was determined to be about 3 min. About 35% of the injected radioactivity was excreted in the urine and about 55% in the feces. Twenty-three urinary metabolites were identified. The metabolites included beta-oxidized and omega-oxidized products as well as metabolites in which the 9-methylene group had been biotransformed.